10月3日 - ** 药物开发商Ovid Therapeutics OVID.O股价盘前上涨20%至1.97美元
** 该公司称其试验性癫痫药物OV329在早期试验中显示出强烈的有效性迹象
** 该药物正在开发中，用于治疗抗药性癫痫，这是一种只影响一侧大脑和身体的癫痫发作类型。
** 研究显示，OV329通过阻断一种分解镇静化学物质的酶，有助于提高大脑中镇静化学物质的水平，这可能有助于减少癫痫发作。
** 奥维德公司称，OV329的疗效不亚于或优于用于治疗癫痫发作的老药维加巴曲林。
** 截至上次收盘，该公司股价年累计上涨了 75
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.